Quarterly Results, Profit & Loss, Balance Sheet, Cash Flows, and Ratios are shown below as separate sections.
Financials of SAIPARENT
Quarter-by-quarter operating performance
| Dec 2025 | Mar 2026 | |
|---|---|---|
| Sales + | 96 | 198 |
| Expenses + | 100 | 172 |
| Operating Profit | -4 | 26 |
| OPM % | -4% | 13% |
| Other Income + | 3 | 3 |
| Interest | 5 | 8 |
| Depreciation | 6 | 8 |
| Profit before tax | -12 | 12 |
| Tax % | -43% | -6% |
| Net Profit + | -7 | 13 |
| EPS in Rs | -1.80 | 2.98 |
Financials of SAIPARENT
Annual income statement trend
| Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|
| Sales + | 97 | 154 | 163 | 381 |
| Expenses + | 78 | 122 | 124 | 342 |
| Operating Profit | 19 | 32 | 39 | 39 |
| OPM % | 19% | 21% | 24% | 10% |
| Other Income + | 0 | 1 | 1 | 9 |
| Interest | 6 | 11 | 12 | 18 |
| Depreciation | 6 | 9 | 8 | 17 |
| Profit before tax | 7 | 13 | 20 | 12 |
| Tax % | 40% | 33% | 28% | -20% |
| Net Profit + | 4 | 8 | 14 | 14 |
| EPS in Rs | 6.13 | 6.36 | 5.43 | 3.23 |
| Dividend Payout % | 0% | 0% | 0% | 0% |
Financials of SAIPARENT
Capital structure and asset base
| Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|
| Equity Capital | 7 | 13 | 13 | 22 |
| Reserves | 24 | 61 | 80 | 469 |
| Borrowings + | 69 | 119 | 94 | 333 |
| Other Liabilities + | 34 | 75 | 85 | 600 |
| Total Liabilities | 134 | 268 | 272 | 1,424 |
| Fixed Assets + | 44 | 70 | 53 | 364 |
| CWIP | 2 | 0 | 0 | 212 |
| Investments | 0 | 0 | 0 | 0 |
| Other Assets + | 88 | 198 | 219 | 848 |
| Total Assets | 134 | 268 | 272 | 1,424 |
Financials of SAIPARENT
Operating, investing and financing cash movement
| Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|
| Cash from Operating Activity + | -13 | -30 | 33 | 93 |
| Cash from Investing Activity + | -19 | -46 | 0 | -274 |
| Cash from Financing Activity + | 24 | 79 | -36 | 596 |
| Net Cash Flow | -8 | 2 | -2 | 415 |
| Free Cash Flow | -30 | -72 | 41 | -184 |
| CFO/OP | -54% | -94% | 86% | 253% |
Financials of SAIPARENT
Working capital efficiency and return ratios
| Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|
| Debtor Days | 231 | 302 | 283 | 173 |
| Inventory Days | 83 | 143 | 199 | 259 |
| Days Payable | 140 | 203 | 225 | 224 |
| Cash Conversion Cycle | 174 | 242 | 256 | 208 |
| Working Capital Days | 19 | 72 | 79 | -161 |
| ROCE % | 16% | 17% | 6% |
The company is confident of achieving 20%+ volume growth backed by steady ramp-up in Jammu and existing facilities. Key concall takeaways from Innova Captab…
Chronic respiratory segment in India showing over 25% growth; oncology and cardiovascular segments also strong. Key concall takeaways from Glenmark…
Capex of ₹250 crore planned over 2-2.5 years to enhance capacity and build warehouse, supporting growth (Page 14). Key concall takeaways from Ind-Swift…
400 crores revenue by FY30, with sustained strong customer demand and portfolio expansion. Key concall takeaways from Hikal Ltd's Q1 FY27 earnings call — and…